sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 40 NHL

1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms

return to top


RTF-CCR SAKK clinical research grant - open for application



Rising Tide Foundation for Clinical Cancer Research (RTF-CCR) is proud to enter into its third year of Clinical Cancer Research Grant partnership with the Swiss Group for Clinical Cancer Research (SAKK) and Gateway for Cancer Research (Gateway).


Application deadline: May 20, 2015. Click here for more information and application downloads.


The grant is focused on addressing 5 critical challenges in clinical cancer research and endowed with a total of USD 1.500.000. Investigators are challenged to submit research proposals for innovative, patient-centered clinical cancer trials. 


The winning proposal will be announced in November 2015.

1. Overview


Intensified CHOP followed by Triple High-Dose Chemotherapy with Autologous Stem Cell Support as First Line Treatment for High-Risk Non Hodgkin Lymphoma: A Phase II Study.



Study details

Type of study

Prospective Phase II study

Target number of patients


Date of activation


Approved by

CKVO Status: December 30, 1998 Approved
CKVO 98-05

2. Patient eligibility criteria

Inclusion criteria

Biopsy proven primary NHL of high or intermediate histology.
No prior treatment
Belonging to the high risk group
Measurable or evaluable tumour lesion
WHO performance 0, 1 or 2
Ages between 18 and 65 years
Informed consent

Exclusion criteria

Mantle cell lymphoma
Lymphoblastic lymphoma
Burkitt?s lymphoma
HIV positivity
Prior malignancy, except skin (non-melanoma), or cervix carcinoma stage I
Severe major organ dysfunction or metabolic disease
Inadequate liver or renal function, unless due to NHL
CNS involvement of NHL

3. Registration (& randomization) of patients


Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...:

Registration criteria

The following information will be requested:

Protocol number
Name institute
Name caller/physician who will treat the patient
Initials of patient
Hospital record number
Date of birth
Pathological diagnosis
LDH and upper normal limit of local laboratory
WHO performance

4. Participating parties

Principal investigator

GW van Imhoff (

Coordinating investigator(s)

LF Verdonck (


B. van der Holt (

Trial manager

M van Os (

Central data management

M van Os (

Other functions

Pathology Reviewer:
S Poppema

5. Participating sites

6. Instruction videos

7. Download documentation / forms


return to top